Wilovast Special Precautions

Rosuvastatin should be used with caution in patients who have a history of liver disease and/or consume substantial quantities of alcohol. Unexplained persistent transaminase elevations or active liver disease are contraindications to the use of Rosuvastatin. Rosuvastatin should be prescribed with caution in patients with predisposing factors for myopathy, such as renal impairment, advanced age, and inadequately treated hypothyroidism. As an HMG-CoA reductase inhibitor, effects of Rosuvastatin on skeletal muscle are uncomplicated myalgia, and myopathy. Patients should be advised to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Rosuvastatin therapy should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected.
The risk of myopathy during treatment with Rosuvastatin may be increased with concurrent administration of other lipid lowering therapies, cyclosporine or lopinavir/ritonavir. Rosuvastatin therapy should also be temporarily withheld in any patient with an acute serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic endocrine and electrolyte disorders or uncontrolled seizures).
Combination therapy of Rosuvastatin and Gemfibrozil should generally be avoided.